Skip to main navigation

About Us
Our Science
Our Products
Our Pipeline
- Overview
- Ublituximab
- Azer-Cel
- TG-1701
- TG-1801
Our Publications
Our Trials
- Trial Information
- Expanded Access Policy
Investors & Media

CAREERS
CONTACT US
Twitter

Close

About Us
Our Science
Our Products
Our Pipeline
- Overview
- Ublituximab
- Azer-Cel
- TG-1701
- TG-1801
Our Publications
Our Trials
- Trial Information
- Expanded Access Policy
Investors & Media

Investors
& Media

Event Details

TG Therapeutics Q2 2023 Financial Results and Business Update

Aug 01, 2023 at 8:30 AM EDT

Listen to Webcast

Share facebook linkedin twitter

Component-5--2

TG Therapeutics © . All rights reserved.

Join us
Contact Us
Privacy Policy
Terms of Use